NCT06312176 · Interventional trial
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Overall registry status Recruiting
Phase 3
Conditions Breast Neoplasms
Delaware Valley sites
- Thomas Jefferson University - Clinical Research Institute ( Site 0056) · Philadelphia, PA · Philadelphia County · Recruiting
First posted
Registry updated
Added to the directory